The dermatology drugs market is expected to reach $34.5 billion by 2023, a new report suggests. Research and Markets says that, among topical corticosteroids, retinoids, biologics, calcineurin inhibitors, antihistamines, hormonal therapy, and others, biologics are expected to be the fastest growing category, advancing at CAGR of 9.1% during the forecast period.

The dermatology drugs market saw the highest revenue generated from psoriasis drugs during the historical period evaluated. The category generated revenue of $14.2 billion in the market in 2017. 

The full report is available online